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ABSTRACT
The objective of the present study was to investigate the effect of oﬂ oxacin (10 mg/kg) on the 
pharmacokinetics of meloxicam (0.5 mg/kg) in goats, when administered concurrently by intravenous route. 
Meloxicam concentration in plasma was measured using HPLC assay. The pharmacokinetics of meloxicam 
were best described by the two-compartment open model. Following concurrent administration of meloxicam 
and oﬂ oxacin, the mean plasma level of meloxicam was only found to be signiﬁ cantly higher (P<0.05) at 15 
min compared to its alone administration. Statistical analysis of data revealed that there were no statistically 
signiﬁ cant differences in PK parameters between the two treatments, except K
21
. Therefore, the results of the 
present study suggest that concurrent administration of oﬂ oxacin and meloxicam in goats does not require any 
adjustment in dosage regimens. Based on PK determinants, meloxicam may be administered by i.v. route at 0.86 
and 0.65 mg/kg, as loading and maintenance doses respectively, and is to be repeated at 8 h intervals.
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Introduction
Meloxicam is known to preferentially inhibit cyclo-oxygenase-2 and is not only 
effective in the treatment of inﬂ ammatory conditions, but also does not adversely affect 
platelet aggregation or renal prostaglandin biosynthesis (VANE and BOTTING, 1995; 
ALENCAR et al., 2002). The pharmacokinetics of meloxicam have been investigated in 
rabbits (TURNER et al., 2006), cats (LEHR et al., 2009), dogs (BUSCH et al., 1998; MONTOYA 
et al., 2004), sheep and goats (SHUKLA et al., 2007), piglets (FOSSE et al., 2008), horses 
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(LEES et al., 1991; TOUTAIN et al., 2004), chickens and four other species of birds (BAERT 
and DE BACKER, 2003), calves (MOSHER et al., 2012) and vultures (NAIDOO et al., 2008). 
Good absorption, longer elimination half-life and optimum bioavailability attributes 
make it an ideal and suitable NSAID for use in animals (BUSCH et al., 1998).
NSAIDs and antibacterials, including ﬂ uoroquinolones, are often used concomitantly 
in clinical practice. Fluoroquinolones have been reported to interact with NSAIDs at the 
pharmacokinetic and pharmacodynamic level (LANGTRY and LAMB, 1998). On concurrent 
administration, gatiﬂ oxacin has been reported to alter the pharmacokinetics of meloxicam 
in buffalo calves (DUMKA et al., 2007). The elimination half-life of meloxicam was found to 
be signiﬁ cantly reduced in the presence of enroﬂ oxacin, as compared to meloxicam alone 
(TOPPO et al., 2011). Similarly, VERMA et al. (2007) reported that meloxicam prolonged the 
retention time of enroﬂ oxacin and ciproﬂ oxacin in goats. However, AHMED et al. (2005) 
did not observe any signiﬁ cant alteration in the pharmacokinetic proﬁ le of enroﬂ oxacin 
in calves in the presence of diclofenac sodium.
Although the PK proﬁ le of meloxicam alone (SHUKLA et al., 2007) or oﬂ oxacin alone 
(BARUAH et al., 2004) have been reported in goats, no studies have been undertaken on the 
pharmacokinetic interaction between these two drugs when administered concomitantly. 
Therefore, the present study was undertaken to determine the inﬂ uence of oﬂ oxacin on the 
disposition kinetics of meloxicam following their concurrent intravenous administration 
in goats.
Materials and methods 
Experimental animals. Ten healthy female Barberi goats, aged between 1.2 and 2.0 
years and weighing 18 to 22 kg, were procured from the livestock farm of the University. 
The animals were examined for apparent clinical signs of illness prior to starting the 
study and they were maintained under standard management conditions and provided 
concentrate feed, green fodder and straw. The animals had free access to drinking water. 
All the animals were dewormed using a single oral dose of fenbendazole at 5 mg/kg prior 
to the start of the experiment. A minimum washout period of 21 days was allowed between 
different treatments (oﬂ oxacin and meloxicam). The experimental protocol was approved 
by the Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) on the recommendation of the Institutional Animal Ethics Committee (IAEC).
Drugs and chemicals. For preparation of the standard curve, meloxicam was purchased 
from Sigma-Aldrich. Injectable oﬂ axacin (Olone- DS; Rodec Pharmaceuticals Pvt. Ltd., 
New Delhi) and meloxicam (Melonex; Intas Pharmaceutical Ltd., Ahmedabad) were 
purchased from the local market. HPLC grade water was prepared in the laboratory using 
Millipore water puriﬁ cation assembly (Milli-Q) and all the chemicals and solvents used 
were of HPLC grade. 
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Experimental design. Ten healthy female goats were divided into two groups, I and 
II of ﬁ ve animals each, which were used separately for PK studies on meloxicam and 
oﬂ oxacin alone, respectively. Thereafter, three animals from each group were randomly 
selected for interaction studies between meloxicam and oﬂ oxacin, therefore, the only 
meloxicam group consisted of ﬁ ve goats while the interaction group consisted of six 
animals.
Dosing and sampling. Meloxicam was injected into ﬁ ve goats in Group I by 
intravenous (IV) route at the dose rate of 0.5 mg/kg body weight. In the other group 
of six animals, meloxicam (0.5 mg/kg) and oﬂ oxacin (10 mg/kg) were concurrently 
administered through opposite jugular veins. Blood samples for estimation of meloxicam 
from each goat were collected from the contralateral jugular vein into heparinized tubes 
before drug administration (0 hour) and at 2.5, 5, 10, 15, 30, 45 minutes and 1, 1.5, 2, 
3, 4, 6, 8, 12, 18, 24, 30, 36 and 48 hours post-drug administration. Blood samples were 
centrifuged at 3000 rpm for 20 min to separate plasma. Plasma samples were stored in 
storage vials at -20 °C until assayed.
Extraction of meloxicam from plasma. Meloxicam was extracted from plasma 
samples employing the slightly modiﬁ ed extraction method for enroﬂ oxacin (NIELSEN 
and GYRD-HANSEN, 1997). For deproteinization, 0.5 mL HPLC grade acetonitrile was 
added into a 0.5 mL plasma sample. The mixture was vortexed and centrifuged at 9000 
rpm for 10 min. The supernatant (0.5 mL) was collected in a microcentrifuge tube and 
0.5 mL of HPLC grade water was added. This mixture was ﬁ ltered through a 0.22 μm 
Millipore cellulose acetate membrane ﬁ lter and an aliquot of 20 μL of the sample was 
injected into the HPLC system for assay of meloxicam. 
 Assay method. HPLC system (Waters, USA), having a photodiode array detector 
with Empower software and C18 reverse phase column (particle size 5 μm; 4.6 x 250 
mm, Waters Spherosorb), was used for assay of meloxicam in blood, employing the 
modiﬁ ed HPLC method of DASANDI et al. (2002).
The mobile phase was prepared using 60% buffer and 40% acetonitrile. The buffer 
used consisted of 170 mM sodium acetate trihydrate in water and 0.12% v/v triethylamine, 
and its pH was adjusted to 3.3 using acetic acid. The detection wavelength was set at 355 
nm. 20 μL samples were injected at a mobile phase ﬂ ow rate of 1.20 mL/min and at an 
ambient temperature of 25.0 ± 0.5 °C. Retention time of meloxicam was 4.6 ± 0.1 min. A 
stock solution (100 μg/mL) of meloxicam was prepared in HPLC water. 
Working plasma standards were prepared from the stock solution of meloxicam 
in pooled plasma from untreated goats. The method was found to be consistent and 
reproducible, and the standard curve was linear in the concentration range of 0.1 to 6.40 
μg/mL, and the correlation coefﬁ cient (R^2) was 0.999. The intra-day and inter-day 
coefﬁ cients of variation were less than 10 per cent. Mean recovery was more than 90 per 
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cent. Goat blank plasma produced no endogenous interferences in meloxicam retention 
time.
Pharmacokinetics and statistical analysis of data. The plasma meloxicam 
concentration time proﬁ le of each animal following intravascular administration were 
used to determine the pharmacokinetic variables, employing a non-linear iterative curve 
ﬁ tting the computer program PHARMKIT (version 2.10, Johnson and Woolard, 1988), 
and other parameters were determined using the equations described by BAGGOT (1977) 





 which were expressed as harmonic mean values. The data generated was subjected 
to statistical analysis employing the Student′s t-test (SNEDECOR and COCHRAN, 1967). 
The dosage regimen of meloxicam was computed using the equations suggested by 
BAGGOT (1977).
Results
Following single intravenous injection (0.5 mg/kg), the mean plasma level of 
meloxicam was found to be 2.99 ± 0.13 μg/mL at 2.5 min, which rapidly decreased to 
1.85 ± 0.11 μg/mL at 15 min, and thereafter gradually to 0.22 ± 0.03 μg/mL at 12 h as 
summarized in Table 1 and shown in Fig. 1.
Evaluation of the observed plasma levels of meloxicam versus time data indicated 
that the data could be best ﬁ tted to a two-compartment open model and adequately 
described by the biexponential equation:
  CP = Ae-αt + Be-βt 
where Cp is the plasma concentration of meloxicam at time t, A and B are the zero 
time plasma drug concentration intercepts of the biphasic disposition curves, and α and β 
are the ﬁ rst order rate constants of distribution and elimination phases, respectively and 
“e” is the base of natural logarithm. The detailed pharmacokinetic parameters obtained by 
compartmental analysis are presented in Table 2.
The mean values of distribution half-life (t
½α
) and elimination half-life (t
½β
) of 
meloxicam in goats were found to be 5.77 min and 234.85 min, respectively. The average 
values for the area under plasma drug concentration time curve (AUC), the area under 
the ﬁ rst moment curve (AUMC), apparent volume of distribution (Vd
(area)
) and total body 
clearance (Cl
B
) were 601.72 ± 42.77 μg.min/mL, 205095.9 ± 22941.00 μg.min2 /mL, 0.28 
± 0.02 L/kg and 0.00085 ± 0.01 L/min/kg, respectively. The value of K
21
 was 0.061 ± 0.01 
min-1 while the ratio of drug concentration between tissue and central compartment (T/P) 
was 0.88 ± 0.16, and the overall mean residence time (MRT) was 336.31 ± 14.61 min.
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Table 1. Comparative plasma meloxicam concentrations (mean ± SE) following single 
intravenous administration of meloxicam (0.5 mg/kg) alone and concurrent administration of 
meloxicam (0.5 mg/kg) and oﬂ oxacin (10 mg/kg) in goats
Time (Min) Mean plasma concentrations (μg/mL)
Meloxicam (n = 5) Oﬂ oxacin + Meloxicam (n = 6)
2.5 2.99 ± 0.13 3.35 ± 0.12
5 2.50 ± 0.18 2.93 ± 0.12
10 2.20 ± 0.13 2.45 ± 0.09
15 1.85 ± 0.11 2.20 ± 0.08*
30 1.71 ± 0.11 1.80 ± 0.08
45 1.59 ± 0.10 1.64 ± 0.09
60 1.45 ± 0.07 1.47 ± 0.07
90 1.22 ± 0.06 1.30 ± 0.08
120 1.08 ± 0.08 1.15 ± 0.05
180 0.97 ± 0.04 0.84 ± 0.07
240 0.80 ± 0.05 0.68 ± 0.08
360 0.58 ± 0.04 0.47 ± 0.05
480 0.39 ± 0.07 0.34 ± 0.04
720 0.22 ± 0.03 0.20 ± 0.02
*P <0.05
Fig. 1. Semilogarithmic plot of comparative meloxicam levels following a single intravenous 
administration of meloxicam (0.5 mg/kg) alone and concurrent administration of meloxicam (0.5 
mg/kg) and oﬂ oxacin (10 mg/kg) in goats. Data presented are mean ± SE of 5-6 animals. *P<0.05.
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Table 2. Comparative pharmacokinetic parameters of meloxicam (mean ± SE) following single 
intravenous administration of meloxicam alone and concurrent administration of meloxicam and 
oﬂ oxacin in goats
Parameters (Units) Meloxicam (n = 5) Oﬂ oxacin + Meloxicam (n = 6)
A (μg/mL) 1.65 ± 0.19 1.92 ± 0.12
B (μg/mL) 1.70 ± 0.08 1.77 ± 0.07
α (min-1) 0.11 ± 0.01 0.09 ± 0.00
β (min-1) 0.003 ± 0.00 0.003 ± 0.00
t
½α
 (min)    5.77#       7.40#
t
½β 
(min) 234.85#   213.75#
AUC (μg.min/mL) 601.72 ± 42.77 568.47 ± 35.11
AUMC (μg.min2 /mL) 205095.90 ± 22941.00 179848.2 ± 18436.40
MRT (min) 336.31 ± 14.61 312.20 ± 16.49
Vd
area
( L/kg) 0.28 ± 0.02 0.27 ± 0.01
Vdss (L/kg) 0.28 ± 0.01 0.27 ± 0.01
Cl
B
 (L/min/kg) 0.00085 ± 0.01 0.0009 ± 0.00005
K
el
 (min-1) 0.0056 ± 0.00 0.0066 ± 0.00
K
12
 (min-1) 0.05 ± 0.01 0.04 ± 0.00
K
21





 (ratio) 0.88 ± 0.11 0.93 ± 0.06
Vc (L/kg) 0.15 ± 0.01 0.14 ± 0.005
Vp (L/kg) 0.13 ± 0.01 0.13 ± 0.008
T/P (ratio) 0.88 ± 0.16 0.98 ± 0.03
f
c
 (ratio) 0.54 ± 0.04 0.50 ± 0.00
#Harmonic mean values ; *P <0.05; A - zero time intercept of the distribution phase; B - zero time intercept 
of the elimination phase; t
½α
 - distribution half-life; t
½ - elimination half-life; α - distribution rate constant;  - 
elimination rate constant; AUC - total area under the plasma drug concentration time curve; AUMC - total area 
under the ﬁ rst moment of plasma drug concentration time curve; K
el
 - the elimination rate constant of the drug 
from central compartment; K
21
 - the rate constant of transfer of drug from tissues to the central compartment; K
12
 
- the rate constant of transfer of drug from the central to tissue compartment; f
c
 - fraction of drug present in the 
central compartment; Vd
area
 - the volume of distribution of drug based on area; Vc - the volume of distribution 
of drug in central compartment; Vp - the volume of distribution of drug in peripheral compartment; Vd
ss
 - the 
volume of distribution of drug at steady state; Cl
B
 - the total body clearance of drug; T/P - ratio of the drug 
concentration between peripheral and the central compartment; MRT - mean residence time. 
Following concurrent administration of meloxicam and oﬂ oxacin by intravenous 
route, mean plasma concentration of meloxicam was found to be 3.35 ± 0.12 μg/mL at 
2.5 min, which rapidly declined to 1.80 ± 0.08 μg/mL at 30 min and thereafter slowly to 
0.20 ± 0.02 μg/mL at 12 h of drug administration. 
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 were 568.47 ± 35.11 μg.min/mL, 179848.2 ± 18436.40 μg.min2/mL, 0.27 ± 
0.01 L/kg and 0.0009 ± 0.00005 L/min/kg, respectively. The ratio of drug concentration 
between tissue and central compartment (T/P) was 0.98 ± 0.03 and the overall mean 
residence time (MRT) was found to be 312.2 ± 16.49 min.
Discussion 
Evaluation of the semilogarithmic plot of plasma meloxicam concentration-time data 
following its administration alone or concurrent administration with oﬂ oxacin indicated 
the two-compartment pharmacokinetic behaviour of meloxicam in goats, as has been 
reported in horses (LEES et al., 1991), chickens (BAERT and DE BACKER, 2003) and sheep 
(SHUKLA et al., 2007).
Following intravenous administration of meloxicam in goats, higher values of the 
distribution rate constant (0.11 min-1) and the corresponding short distribution half-life of 
5.77 min indicated the rapid distribution of meloxicam in goats. However, a many times 
higher distribution half-life value of the test drug has been reported in sheep (0.41 ± 0.20 
h; SHUKLA et al., 2007) and horses (0.40 ± 0.2 h: LEES et al., 1991). 
The elimination half-life of meloxicam in the present study in goats was found to be 
234.85 min, however, SHUKLA et al. (2007) observed a comparatively higher (6.73 h) value 
in goats. Compared to the elimination half-life values observed in goats in the present 
study or those reported by SHUKLA et al. (2007), longer elimination half-life values of 
8.54 h, 24.0 h and 10.85 h have been reported in horses, dogs and sheep after intravenous 
administration at 0.6 mg/kg, 0.2 mg/kg, 0.5 mg/kg, respectively (TOUTAIN et al., 2004; 
BUSCH et al., 1998; SHUKLA et al., 2007). However, comparatively shorter elimination half-
lives have been documented in chickens (3.2 h; BAERT and DE BACKER, 2003) and pigs 
(2.7 h; FOSSE et al., 2008).These observations evidently reveal marked species dependent 
differences in the disposition kinetic behaviour of meloxicam. Goats have greater drug 
metabolizing enzyme activities in the liver and other organs, and eliminate antipyrine, 
sulphadimidine and isometamidium at a signiﬁ cantly faster rate than sheep (ELSHEIKH 
et al., 1988, 1991a, 1991b, 1997; WESONGAH et al., 2004), therefore, the short elimination 
half-life of meloxicam in goats compared to sheep, horse and dogs is expected.
In the present study, the AUC value of meloxicam in goats was 601.72 μg/mL. min, 
but higher AUC values have been documented in sheep (31.88 μg/mL.h; SHUKLA et al., 
2007) and horses (18.8 μg /mL.h; SINCLAIR et al., 2006).
The mean value of the apparent volume of distribution (Vd
area
) of meloxicam in goats 
in the present study was calculated to be 0.28 L/Kg, which was almost comparable to that 
of 0.27 L/kg in horses (SINCLAIR et al., 2006) 0.25 L/kg in sheep (SHUKLA et al., 2007) but 
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higher than that reported in pigs (0.19 L/kg: FOSSE et al., 2008). The Vd
area
 value obtained 
in the present study and reported in other species indicates that the drug is not freely 
distributed to different body tissues and ﬂ uids, which may be due to the relatively high 
ionization state of meloxicam at physiological pH and/or its high plasma protein binding, 
as reported in other species (SCHMID et al., 1995; BUSCH et al., 1998).
The mean residence time provides a useful estimate of the persistence time of a drug 
in the body. In the present study, the MRT value of meloxicam in goats was 336.31 min 
but comparatively lower values of MRT have been reported in mice (3.02 h) and chickens 
(4.41 h) by BUSCH et al. (1998) and BAERT and DE BACKER (2003), respectively, contrary 
to the higher values in sheep (15.13 h) and dogs (34.8 h) by SHUKLA et al. (2007) and 
BUSCH et al. (1998), respectively. 
The total body clearance of meloxicam in goats in the present study was 0.00085 
L/min/kg and this value was almost three times higher than in sheep ( 0.016 L/h/kg; 
SHUKLA et al., 2007) and conspicuously higher than in horse (0.034 L/h/kg; SINCLAIR et 
al., 2006) and dogs (0.01 L/h/kg; BUSCH et al., 1998) but almost comparable to that of 0.06 
L/h/kg in pigs (FOSSE et al., 2008).
Mean meloxicam plasma levels, following concurrent IV administration of 
meloxicam (0.5 mg/kg) and oﬂ oxacin (10 mg/kg), were higher compared to the 
meloxicam alone group at 2.5 min to 45 min However, it was only statistically signiﬁ cant 
at 15 min, and thereafter the plasma levels either did not differ or were slightly lower in 
the meloxicam+oﬂ oxacin concurrent group. Statistical analysis of the pharmacokinetic 
data from the meloxicam alone and the meloxicam+oﬂ oxacin concurrent groups revealed 
that none of the pharmacokinetic determinants differed signiﬁ cantly from each other, 
except K
21
 which was signiﬁ cantly lower in the latter group. These observations therefore 
suggest that there is no signiﬁ cant interaction between meloxicam and oﬂ oxacin, except a 
slight possibility of a reduced rate of transfer of the drug from the peripheral compartment 
to the central compartment. Therefore, the PK interaction between the two drugs did not 
seem to be clinically important and does not require readjustment in dosage regimens. 
In human whole blood, meloxicam has been found to inhibit 50% COX-1 activity 
(IC
50
) at 1.15 μg/mL while COX-2 activity at 0.088 μg/mL (PAIRET et al., 1998). Therefore, 
meloxicam is considered to be a selective COX-2 inhibitor. The effective plasma 
concentration of meloxicam has been reported to be 0.73 μg/mL in horses (TOUTAIN 
et al., 2004). Based on the in vitro EC
50
 value of 0.088 μg/mL (reported in human whole 
blood) and the observed mean plasma concentrations of meloxicam in goats above for up 
to 12 h (0.22 μg/mL), it may be inferred that a 0.5 mg/kg dosage level of meloxicam is 
sufﬁ cient for a satisfactory therapeutic effect in goats. However, taking into considerations 
the effective plasma concentration of meloxicam reported in horses (0.73 μg/mL) and the 
PK determinants in goats in the present study, the loading and maintenance doses of 
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meloxicam were found to be 0.86 and 0.65 mg/kg, respectively and should be repeated at 
8 h inter vals. Pharmacokinetic interaction between oﬂ oxacin and meloxicam in goats is 
not substantive and does not warrant any adjustment of dosage regimen as a result of its 
concurrent use with oﬂ oxacin.
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SAŽETAK
Istražen je učinak oﬂ oksacina (10 mg/kg) na farmakokinetiku meloksikama (0,5 mg/kg) u koza pod uvjetima 
istodobne intravenske primjene.  Koncentracija meloksikama u plazmi utvrđena je visokotlačnom tekućinskom 
kromatograﬁ jom. Kao najbolji model za opis njegove farmakokinetike korišten je otvoreni model s dvama 
odjeljcima. Istodobnom primjenom meloksikama i oﬂ oksacina, srednja razina meloksikama u plazmi bila je 
statistički značajno viša  (P<0,05) samo 15 minuta u usporedbi s primjenom samog meloksikama. Statistička 
analiza podataka pokazala je da između dva načina primjene ne postoje značajne razlike farmakokinetičkih 
pokazatelja, osim za K
21
. Rezultati istraživanja pokazuju da kod koza doziranje oﬂ oksacina i meloksikama 
prilikom njihove istovremene primjene ne treba mijenjati. Na temelju farmakokinetičkih pokazatelja, 
meloksikam se može primijeniti intravenski u početnoj dozi od 0,86 mg/kg, te u dozi za održavanje od 0,65 mg/
kg, uz ponavljanje u vremenskim razmacima od 8 sati.
Ključne riječi: meloksikam, oﬂ oksacin, visokotlačna kromatograﬁ ja, farmakokinetika, koze ________________________________________________________________________________________
.
